Erdoğan Beril, Uzaslan Esra, Budak Ferah, Karadağ Mehmet, Ediger Dane, Oral Barbaros, Göral Güher, Ege Ercüment, Gözü Oktay
Department of Chest Diseases, Faculty of Medicine, Uludağ University, Bursa, Turkey.
Tuberk Toraks. 2005;53(2):127-31.
Fas-Fas Ligand (FasL) is one of the major mediator system that activates programmed cell death. Cleavage of membranebound FasL by a metalloproteinase-like enzyme resulted in the formation of soluble FasL (sFasL). sFasL as well as the transmembrane form of FasL binds to Fas and transduces apoptotic signal in Fas-expressing cells. It's suggested that soluble Fas (sFas) and sFasL has an impact on tumor progress and immune escape feature of tumor cells from the host immune system. Since Fas antigen expression in the lungs has been localized to alveolar and bronchial epithelial cells, in this study we aimed to investigate the sFas (pg/mL) and sFasL levels (pg/mL) of bronchoalveolar lavage (BAL) fluid in lung cancer patients. Study population was consisted of 27 patients with lung cancer (mean age 62.9 +/- 10.7 years, 25 control subjects (mean age 47.9 +/- 13.9 years). BAL was performed under local anesthesia, on the unaffected lung of patients; either subsegments of right middle or lingula. BAL sFas and sFasL were evaluated by using ELISA method. The mean levels of sFas was 60.8 +/- 56.8 in lung cancer patient and 39.5 +/- 25.9 in control subjects (p> 0.05). The mean levels of sFasL was 51.6 +/- 39.2 in cancer patient and 41.2 +/- 27.4 in control subjects (p> 0.05). In conclusion, although we did not observe any significant difference between two groups, higher BAL levels of sFas and sFasL levels in lung cancer patients than control subjects, made us thought that apoptosis might have a role development and progression of lung cancer.
Fas-Fas配体（FasL）是激活程序性细胞死亡的主要介导系统之一。一种类金属蛋白酶样酶对膜结合型FasL的切割导致了可溶性FasL（sFasL）的形成。sFasL以及FasL的跨膜形式与Fas结合，并在表达Fas的细胞中传导凋亡信号。有研究表明，可溶性Fas（sFas）和sFasL对肿瘤进展以及肿瘤细胞逃避宿主免疫系统的免疫逃逸特性有影响。由于肺组织中Fas抗原的表达已定位在肺泡和支气管上皮细胞，因此在本研究中，我们旨在调查肺癌患者支气管肺泡灌洗（BAL）液中的sFas（pg/mL）和sFasL水平（pg/mL）。研究人群包括27例肺癌患者（平均年龄62.9±10.7岁）和25例对照受试者（平均年龄47.9±13.9岁）。在局部麻醉下对患者未受影响的肺（右中叶或舌叶的亚段）进行BAL。采用酶联免疫吸附测定（ELISA）法评估BAL中的sFas和sFasL。肺癌患者的sFas平均水平为60.8±56.8，对照受试者为39.5±25.9（p>0.05）。癌症患者的sFasL平均水平为51.6±39.2，对照受试者为41.2±27.4（p>0.05）。总之，尽管我们未观察到两组之间有任何显著差异，但肺癌患者BAL中sFas和sFasL水平高于对照受试者这一情况，使我们认为细胞凋亡可能在肺癌的发生和发展中起作用。
